D.J. Leishman

Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: Current recommendations from the Safety Pharmacology Society

D.J. Leishman, Thomas W. Beck, Noël Dybdal et al. · Journal of Pharmacological and Toxicological Methods · 2011 · 103 citations

Cardiovascular Toxicity, Hypertension, Cardiovascular Disease +11

Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin

Rona S. Duncan, Mark J. McPate, John Ridley et al. · Biochemical Pharmacology · 2007 · 57 citations · Full text

Identification of a Low Molecular Mass (14.2 kDa) α-Tocopherol-Binding Protein in the Cytosol of Rat Liver and Heart

Asim K. Duttaroy, D.J. Leishman, Margaret J. Gordon et al. · Biochemical and Biophysical Research Communications · 1993 · 52 citations

Molecular Physiology, Biochemistry, Natural Sciences +8

Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog

Rob Webster, Gill Allan, K. Anto-Awuakye et al. · Xenobiotica · 2001 · 40 citations

Cardiovascular Pharmacology, Pharmacotherapy, Experimental Pharmacology +16

International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug‐induced torsades de pointes

A S Bass, Börje Darpö, Annalisa Breidenbach et al. · British Journal of Pharmacology · 2008 · 30 citations · Full text